AGIO
NASDAQ · Biotechnology
Agios Pharmaceuticals Inc
$32.27
+0.32 (+1.00%)
Financial Highlights (FY 2026)
Revenue
59.22M
Net Income
-452,431,235
Gross Margin
88.3%
Profit Margin
-764.0%
Rev Growth
+56.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.3% | 88.3% | 41.3% | 41.3% |
| Operating Margin | -873.9% | -786.5% | -6.6% | -5.9% |
| Profit Margin | -764.0% | -725.8% | -5.7% | -6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 59.22M | 37.97M | 198.27M | 200.72M |
| Gross Profit | 52.27M | 33.51M | 81.91M | 82.92M |
| Operating Income | -517,500,684 | -298,615,512 | -13,033,249 | -11,761,210 |
| Net Income | -452,431,235 | -261,068,225 | -11,344,752 | -12,565,080 |
| Gross Margin | 88.3% | 88.3% | 41.3% | 41.3% |
| Operating Margin | -873.9% | -786.5% | -6.6% | -5.9% |
| Profit Margin | -764.0% | -725.8% | -5.7% | -6.3% |
| Rev Growth | +56.0% | +56.0% | -2.9% | -8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 267.01M | 273.20M |
| Total Equity | — | — | 1.12B | 1.12B |
| D/E Ratio | — | — | 0.24 | 0.24 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -511,803,145 | -311,734,941 | -15,767,673 | -13,652,238 |
| Free Cash Flow | — | — | -7,306,109 | -10,881,640 |